AKT1 and lung adenocarcinoma: Recently, we also identified RIT1 as a novel driver oncogene in a subset of human lung adenocarcinomas, and our data suggest PI3K/Akt inhibition as a potential therapeutic strategy in RIT1-mutated tumors38.